Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03126630 · OUTCOME

Pharmacokinetics of Anetumab Ravtansine

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma · Source last updated 2026-04-01

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Days 1 and 3 of courses 1 and 8

What was measured

Will be largely descriptive. Changes over time will be plotted and assessed for each patient.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
Will be largely descriptive. Changes over time will be plotted and assessed for each patient.
reporting Status
NOT_POSTED
time Frame
Days 1 and 3 of courses 1 and 8
title
Pharmacokinetics of Anetumab Ravtansine
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice